An interventional study of TMS in PARKINSON DISEASE (Disorder) and Parkinson s Disease, sponsored by San Francisco Neurology and Sleep Center. Recruiting at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by San Francisco Neurology and Sleep Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 554th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 84 that started in 2026, is one of 586 with no phase, reaches primary completion later than 230 of the 384 other live ones, and was the 1,602nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
VA Office of Research and Development · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,650 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 84 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,257 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,650 have an industry lead sponsor. The 10 most frequent:
San Francisco Neurology and Sleep Center is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
San Francisco Neurology and Sleep Center has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
137 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
| NCT06447207Colorado State UniversityOccupational Therapy Led Social Prescription for People With Parkinson Disease | 2026-11-30 |
Add all 137 to your calendar (.ics) → With an account.
Among the 1,650 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) is a brain disorder that causes progressive problems with movement, such as slowness, stiffness, tremor, and difficulty walking. Many people with PD also develop problems with thinking and memory. Current medications can help control movement symptoms but often become less effective over time and may cause side effects. There is a need for additional treatment options that can address both movement and thinking difficulties in PD.
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment that uses magnetic pulses delivered to the scalp to stimulate specific areas of the brain. Previous research has shown that rTMS targeting the motor cortex (the part of the brain that controls movement) can improve motor symptoms in people with PD.
The purpose of this pilot study is to evaluate whether an accelerated course of rTMS targeting the motor cortex can improve movement and thinking abilities in people with mild to moderate Parkinson's disease. The study will enroll 40 participants aged 50 to 90 years at the San Francisco Neurology and Sleep Center.
Participants will receive 6 sessions of rTMS using the EXOMIND™ device, administered twice per week over approximately 3 weeks. Each session delivers high-frequency magnetic stimulation to the motor cortex on both sides of the brain. Participants will be assessed before treatment, at the last treatment session, and at 1-month and 3-month follow-up visits.
The primary outcome measure is the change in motor symptoms as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) at 1 month after treatment. Secondary outcomes include additional measures of walking and gait, domain-specific cognitive testing using the Creyos cognitive battery (assessing memory, attention, reasoning, and other thinking skills), the Montreal Cognitive Assessment (MoCA), depression symptoms (PHQ-9), and quality of life (PDQ-39).
This is a single-center, open-label study with no placebo or control group. Total participation duration is up to 139 days, including screening, treatment, and follow-up visits.
Background and Rationale:
Parkinson's disease (PD) affects approximately 1-2% of adults over age 60 and is characterized by progressive motor symptoms including bradykinesia, rigidity, resting tremor, and postural instability. Cognitive impairment is also common, with approximately 50% of people with PD experiencing mild cognitive impairment and cumulative dementia prevalence reaching up to 80% over the disease course. Current pharmacological treatments provide symptomatic motor benefit but are limited by declining efficacy over time, motor fluctuations, dyskinesias, and other side effects. No disease-modifying therapy is currently available.
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that modulates neural circuits through targeted electromagnetic stimulation. Multiple meta-analyses have demonstrated that rTMS significantly improves motor symptoms in PD, with pooled effect sizes (standardized mean difference) ranging from 0.46 to 0.64. High-frequency rTMS targeting the primary motor cortex (M1) produces the largest motor effect sizes (SMD 0.77-0.79). However, most existing studies have used conventional protocols requiring daily sessions over several weeks, which may limit accessibility and adherence. Additionally, prior studies have relied primarily on global motor assessments and have not systematically characterized the relationship between motor and cognitive changes following rTMS over extended follow-up periods.
Study Design:
This is a single-center, open-label, prospective pilot study conducted at the San Francisco Neurology and Sleep Center. The study consists of three phases: a screening phase (up to 14 days), an open-label treatment phase (approximately 21 days), and a follow-up phase (90 days). Total participation duration is up to 139 days.
Treatment Protocol:
Participants receive 6 sessions of high-frequency rTMS using the EXOMIND™ device (BTL-699-2), administered twice weekly over approximately 3 weeks. Each session delivers stimulation at 10-20 Hz frequency and 90-110% of resting motor threshold (RMT) intensity, with 3,000-6,000 total pulses per session. The target site is the primary motor cortex (M1) bilaterally, localized using the standard motor threshold determination procedure by identifying the scalp position that produces consistent contraction of the contralateral hand muscles. All sessions are conducted on-site with medical staff support.
Assessment Schedule:
Baseline assessments are completed during screening (Day -14 to Day -1) and include motor evaluations, cognitive testing, mood and quality of life questionnaires, vital signs, medical history, TMS safety screening, and calculation of Levodopa Equivalent Daily Dose (LEDD). A Creyos cognitive battery training session is administered at screening to familiarize participants with test procedures and reduce learning effects.
Post-treatment assessments are conducted at three time points: the last treatment session (approximately Day 21), 1-month follow-up (Day 51 ± 7 days), and 3-month follow-up (Day 111 ± 7 days). At each post-treatment time point, the full battery of motor, cognitive, mood, and quality of life assessments is repeated along with vital signs, adverse event assessment, and concomitant medication review.
The cognitive assessment approach uniquely combines the Montreal Cognitive Assessment (MoCA) for global cognitive screening with the Creyos cognitive battery for domain-specific evaluation across six domains: visual spatial working memory, episodic memory, deductive reasoning, mental rotation, verbal short-term memory, and attention. This multi-domain approach is designed to identify which specific cognitive functions may be most responsive to motor cortex rTMS.
Safety Monitoring:
Adverse events are monitored at each treatment session and follow-up visit using a standardized checklist of potential TMS-related adverse effects. Blood pressure and heart rate are recorded at the beginning and end of each treatment session and at all study visits.
Statistical Approach:
Repeated measures ANOVA will assess changes across time points for primary and secondary endpoints. Paired t-tests will evaluate changes between baseline and each post-treatment time point. Cohen's d effect sizes will be calculated for all endpoints. The proportion of participants achieving clinically meaningful improvement will be reported using established minimal clinically important differences (MCID) where available. Both intention-to-treat and per-protocol analyses will be conducted. Last observation carried forward (LOCF) will be used for sensitivity analyses in cases of missing data. A p-value of 0.05 will be considered statistically significant. Exploratory subgroup analyses may be conducted based on baseline motor severity, cognitive status, disease duration, age, and sex.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with mild to moderate idiopathic Parkinson's disease (Hoehn and Yahr stage 1-3) receive 6 sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) using the EXOMIND™ device (BTL-699-2), administered twice weekly over approximately 3 weeks. Each session delivers bilateral stimulation to the primary motor cortex (M1) at 10-20 Hz and 90-110% of resting motor threshold, with 3,000-6,000 total pulses per session. Participants maintain their stable pre-study anti-parkinsonian medication regimen throughout the study. Motor function (MDS-UPDRS-III, Freezing of Gait Questionnaire, Timed Up and Go Test, gait speed), cognitive function (Montreal Cognitive Assessment, Creyos cognitive battery), depressive symptoms (PHQ-9), and quality of life (PDQ-39) are assessed at baseline, last treatment session, 1-month follow-up, and 3-month follow-up.
Device: TMS
The open-label treatment phase will consist of 6 sessions of rTMS using the EXOMIND™ device (BTL-699-2), administered twice a week over approximately 3 weeks. Each session will deliver high-frequency stimulation (10-20 Hz) at 90-110% of resting motor threshold (RMT), with 3,000-6,000 total pulses per session. The target site will be the primary motor cortex (M1), with bilateral stimulation. The motor cortex will be localized using the standard motor threshold determination procedure, identifying the scalp position that produces consistent contraction of the contralateral hand muscles. The procedure will be conducted at San Francisco Neurology and Sleep Center with medical staff support.
Change from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) score at 1-month follow-up
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) is a clinician-rated assessment of motor function in Parkinson's disease. It evaluates 18 items across motor domains including speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, body bradykinesia, postural tremor, kinetic tremor, rest tremor amplitude, and constancy of rest tremor. Each item is scored from 0 (normal) to 4 (severe), yielding a total score range of 0 to 132, with higher scores indicating greater motor impairment. Change from baseline is calculated as the 1-month follow-up score minus the baseline score, with negative values indicating improvement.
Time frame: From baseline to the 1-month follow up
Change from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) score at the last treatment session
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) is a clinician-rated assessment of motor function in Parkinson's disease. It evaluates 18 items across motor domains including speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, body bradykinesia, postural tremor, kinetic tremor, rest tremor amplitude, and constancy of rest tremor. Each item is scored from 0 (normal) to 4 (severe), yielding a total score range of 0 to 132, with higher scores indicating greater motor impairment. Change from baseline is calculated as the last treatment session score minus the baseline score, with negative values indicating improvement.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) score at 3-month follow-up
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) is a clinician-rated assessment of motor function in Parkinson's disease. It evaluates 18 items across motor domains including speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, body bradykinesia, postural tremor, kinetic tremor, rest tremor amplitude, and constancy of rest tremor. Each item is scored from 0 (normal) to 4 (severe), yielding a total score range of 0 to 132, with higher scores indicating greater motor impairment. Change from baseline is calculated as the 3-month follow-up score minus the baseline score, with negative values indicating improvement.
Time frame: From baseline to the end of treatment at 3-month follow-up
Change from baseline in the Montreal Cognitive Assessment (MoCA) score at 1-month follow-up
The Montreal Cognitive Assessment (MoCA) is a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Total Score Range: 0 to 30. Interpretation: Higher scores indicate better cognitive function (a score of 26 or above is generally considered normal). Metric: The change is calculated by subtracting the baseline score from the 1-month follow-up score.
Time frame: From baseline to the 1-month follow up
Change from baseline in the Montreal Cognitive Assessment (MoCA) score at the last treatment session
The Montreal Cognitive Assessment (MoCA) is a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Total Score Range: 0 to 30. Interpretation: Higher scores indicate better cognitive function (a score of 26 or above is generally considered normal). Metric: The change is calculated by subtracting the baseline score from the last treatment score.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change from baseline in the Montreal Cognitive Assessment (MoCA) score at the 3-month follow-up visit
The Montreal Cognitive Assessment (MoCA) is a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Total Score Range: 0 to 30. Interpretation: Higher scores indicate better cognitive function (a score of 26 or above is generally considered normal). Metric: The change is calculated by subtracting the baseline score from the 3-month follow-up score.
Time frame: From baseline to the end of treatment at 3-month follow-up
Change from baseline in the Freezing of Gait Questionnaire (FOG-Q) score at the last treatment session
The Freezing of Gait Questionnaire (FOG-Q) is a patient-reported measure assessing the severity and impact of freezing of gait in Parkinson's disease. It consists of 6 items evaluating gait difficulties, including walking ability, daily impact of gait disturbances, frequency and duration of freezing episodes, and freezing during turning and gait initiation. Each item is scored from 0 (normal) to 4 (most severe), yielding a total score range of 0 to 24, with higher scores indicating more severe freezing of gait. Change from baseline is calculated as the last treatment session score minus the baseline score, with negative values indicating improvement.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change from baseline in the Freezing of Gait Questionnaire (FOG-Q) score at 1-month follow-up
The Freezing of Gait Questionnaire (FOG-Q) is a patient-reported measure assessing the severity and impact of freezing of gait in Parkinson's disease. It consists of 6 items evaluating gait difficulties, including walking ability, daily impact of gait disturbances, frequency and duration of freezing episodes, and freezing during turning and gait initiation. Each item is scored from 0 (normal) to 4 (most severe), yielding a total score range of 0 to 24, with higher scores indicating more severe freezing of gait. Change from baseline is calculated as the 1-month follow-up score minus the baseline score, with negative values indicating improvement.
Time frame: From baseline to the 1-month follow up
Change from baseline in the Freezing of Gait Questionnaire (FOG-Q) score at 3-month follow-up
The Freezing of Gait Questionnaire (FOG-Q) is a patient-reported measure assessing the severity and impact of freezing of gait in Parkinson's disease. It consists of 6 items evaluating gait difficulties, including walking ability, daily impact of gait disturbances, frequency and duration of freezing episodes, and freezing during turning and gait initiation. Each item is scored from 0 (normal) to 4 (most severe), yielding a total score range of 0 to 24, with higher scores indicating more severe freezing of gait. Change from baseline is calculated as the 3-month follow-up score minus the baseline score, with negative values indicating improvement.
Time frame: From baseline to the 3-month follow-up
Change From Baseline in Timed Up and Go Test (TUG) at Last Treatment Session
The Timed Up and Go Test (TUG) is a clinical performance measure of functional mobility and dynamic balance. The test measures the time (in seconds) required for a participant to rise from a standard armchair, walk 3 meters at a comfortable and safe pace, turn around, walk back to the chair, and sit down. A longer time to complete the test indicates greater impairment in functional mobility. Change from baseline is calculated as the post-treatment time minus the baseline time, with negative values indicating improvement.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change From Baseline in Timed Up and Go Test (TUG) at 1-Month Follow-Up
The Timed Up and Go Test (TUG) is a clinical performance measure of functional mobility and dynamic balance. The test measures the time (in seconds) required for a participant to rise from a standard armchair, walk 3 meters at a comfortable and safe pace, turn around, walk back to the chair, and sit down. A longer time to complete the test indicates greater impairment in functional mobility. Change from baseline is calculated as the 1-month follow-up time minus the baseline time, with negative values indicating improvement.
Time frame: From baseline to the 1-month follow-up
Change From Baseline in Timed Up and Go Test (TUG) at 3-Month Follow-Up
The Timed Up and Go Test (TUG) is a clinical performance measure of functional mobility and dynamic balance. The test measures the time (in seconds) required for a participant to rise from a standard armchair, walk 3 meters at a comfortable and safe pace, turn around, walk back to the chair, and sit down. A longer time to complete the test indicates greater impairment in functional mobility. Change from baseline is calculated as the 3-month follow-up time minus the baseline time, with negative values indicating improvement.
Time frame: From baseline to the 3-month follow-up
Change from baseline in Gait Speed as Measured by the 10-Meter Walk Test at the last treatment session
The 10-Meter Walk Test is a clinical performance measure of gait speed. Participants walk a 10-meter distance at their comfortable, self-selected pace, and the time to complete the middle portion of the walkway is recorded to minimize acceleration and deceleration effects. Gait speed is calculated in meters per second (m/s), with lower values indicating slower gait and greater functional impairment. Change from baseline is calculated as the post-treatment gait speed minus the baseline gait speed, with positive values indicating improvement.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change from baseline in Gait Speed as Measured by the 10-Meter Walk Test at 1-month follow-up
The 10-Meter Walk Test is a clinical performance measure of gait speed. Participants walk a 10-meter distance at their comfortable, self-selected pace, and the time to complete the middle portion of the walkway is recorded to minimize acceleration and deceleration effects. Gait speed is calculated in meters per second (m/s), with lower values indicating slower gait and greater functional impairment. Change from baseline is calculated as the 1-month follow-up gait speed minus the baseline gait speed, with positive values indicating improvement.
Time frame: From baseline to the 1-month follow-up
Change from baseline in Gait Speed as Measured by the 10-Meter Walk Test at 3-month follow-up
The 10-Meter Walk Test is a clinical performance measure of gait speed. Participants walk a 10-meter distance at their comfortable, self-selected pace, and the time to complete the middle portion of the walkway is recorded to minimize acceleration and deceleration effects. Gait speed is calculated in meters per second (m/s), with lower values indicating slower gait and greater functional impairment. Change from baseline is calculated as the 3-month follow-up gait speed minus the baseline gait speed, with positive values indicating improvement.
Time frame: From baseline to the 3-month follow-up
Change From Baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) Motor Subscores (Tremor, Rigidity, Bradykinesia, Axial Symptoms) at Last Treatment Session
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) Motor Examination is decomposed into four cardinal motor domain subscores: tremor (items 3.15-3.18, range 0-40), rigidity (item 3.3, range 0-20), bradykinesia (items 3.4-3.8 and 3.14, range 0-44), and axial symptoms (items 3.1, 3.2, 3.9-3.13, range 0-28). Each item is scored 0 (normal) to 4 (severe). Higher scores indicate greater impairment. Change is calculated as post-treatment minus baseline, with negative values indicating improvement.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change From Baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) Motor Subscores (Tremor, Rigidity, Bradykinesia, Axial Symptoms) at 1-Month Follow-Up
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) Motor Examination is decomposed into four cardinal motor domain subscores: tremor (items 3.15-3.18, range 0-40), rigidity (item 3.3, range 0-20), bradykinesia (items 3.4-3.8 and 3.14, range 0-44), and axial symptoms (items 3.1, 3.2, 3.9-3.13, range 0-28). Each item is scored 0 (normal) to 4 (severe). Higher scores indicate greater impairment. Change is calculated as 1-month follow-up minus baseline, with negative values indicating improvement.
Time frame: From baseline to the 1-month follow-up
Change From Baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) Motor Subscores (Tremor, Rigidity, Bradykinesia, Axial Symptoms) at 3-Month Follow-Up
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) Motor Examination is decomposed into four cardinal motor domain subscores: tremor (items 3.15-3.18, range 0-40), rigidity (item 3.3, range 0-20), bradykinesia (items 3.4-3.8 and 3.14, range 0-44), and axial symptoms (items 3.1, 3.2, 3.9-3.13, range 0-28). Each item is scored 0 (normal) to 4 (severe). Higher scores indicate greater impairment. Change is calculated as 3-month follow-up minus baseline, with negative values indicating improvement.
Time frame: From baseline to the 3-month follow-up
Change from baseline in the following domain-specific cognitive measures assessed by the Creyos cognitive battery at the last treatment session
Cognitive performance will be assessed using the Creyos online platform. This measure evaluates specific cognitive domains through validated tasks. For this study, the following domains and their corresponding primary metrics are assessed: Memory (Monkey Ladders Task): Measures visuospatial working memory. Reasoning (Odd One Out Task): Measures deductive reasoning and fluid intelligence. Concentration (Feature Match Task): Measures attention and mental processing speed. Planning (Spatial Planning Task): Measures executive function and strategy. Scoring Parameters: Scale Title: Creyos Cognitive Assessment Score (Standardized Score). Minimum and Maximum Values: Scores are standardized with a mean of 100 and a standard deviation of 15. While theoretically open-ended, the effective range for clinical reporting is typically 0 to 150. Interpretation: Higher scores mean a better outcome, indicating superior cognitive performance relative to the normative database.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change from baseline in the following domain-specific cognitive measures assessed by the Creyos cognitive battery at the 1-month follow-up
Cognitive performance will be assessed using the Creyos online platform. This measure evaluates specific cognitive domains through validated tasks. For this study, the following domains and their corresponding primary metrics are assessed: Memory (Monkey Ladders Task): Measures visuospatial working memory. Reasoning (Odd One Out Task): Measures deductive reasoning and fluid intelligence. Concentration (Feature Match Task): Measures attention and mental processing speed. Planning (Spatial Planning Task): Measures executive function and strategy. Scoring Parameters: Scale Title: Creyos Cognitive Assessment Score (Standardized Score). Minimum and Maximum Values: Scores are standardized with a mean of 100 and a standard deviation of 15. While theoretically open-ended, the effective range for clinical reporting is typically 0 to 150. Interpretation: Higher scores mean a better outcome, indicating superior cognitive performance relative to the normative database.
Time frame: From baseline to the 1-month follow-up
Change from baseline in the following domain-specific cognitive measures assessed by the Creyos cognitive battery at the 3-month follow-up
Cognitive performance will be assessed using the Creyos online platform. This measure evaluates specific cognitive domains through validated tasks. For this study, the following domains and their corresponding primary metrics are assessed: Memory (Monkey Ladders Task): Measures visuospatial working memory. Reasoning (Odd One Out Task): Measures deductive reasoning and fluid intelligence. Concentration (Feature Match Task): Measures attention and mental processing speed. Planning (Spatial Planning Task): Measures executive function and strategy. Scoring Parameters: Scale Title: Creyos Cognitive Assessment Score (Standardized Score). Minimum and Maximum Values: Scores are standardized with a mean of 100 and a standard deviation of 15. While theoretically open-ended, the effective range for clinical reporting is typically 0 to 150. Interpretation: Higher scores mean a better outcome, indicating superior cognitive performance relative to the normative database.
Time frame: From baseline to the 3-month follow-up
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Score at Last Treatment Session
The PHQ-9 is a 9-item self-report measure of depressive symptom severity. Each item is scored 0 (not at all) to 3 (nearly every day), yielding a total score of 0-27. Severity categories: minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). Lower scores indicate fewer depressive symptoms. Change is calculated as post-treatment minus baseline, with negative values indicating improvement.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Score at 1-Month Follow-Up
The PHQ-9 is a 9-item self-report measure of depressive symptom severity. Each item is scored 0 (not at all) to 3 (nearly every day), yielding a total score of 0-27. Severity categories: minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). Lower scores indicate fewer depressive symptoms. Change is calculated as 1-month follow-up minus baseline, with negative values indicating improvement.
Time frame: From baseline to the 1-month follow-up
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Score at 3-Month Follow-Up
The PHQ-9 is a 9-item self-report measure of depressive symptom severity. Each item is scored 0 (not at all) to 3 (nearly every day), yielding a total score of 0-27. Severity categories: minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). Lower scores indicate fewer depressive symptoms. Change is calculated as 3-month follow-up minus baseline, with negative values indicating improvement.
Time frame: From baseline to the 3-month follow-up
Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Score at Last Treatment Session
The PDQ-39 is a 39-item self-report questionnaire assessing health-related quality of life in Parkinson's disease across eight domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Each item is scored 0 (never) to 4 (always). A summary index score is calculated as a percentage (0-100), with lower scores indicating better quality of life. Change is calculated as post-treatment minus baseline, with negative values indicating improvement.
Time frame: From baseline to the end of treatment (approximately Day 21)
Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Score at 1-Month Follow-Up
The PDQ-39 is a 39-item self-report questionnaire assessing health-related quality of life in Parkinson's disease across eight domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Each item is scored 0 (never) to 4 (always). A summary index score is calculated as a percentage (0-100), with lower scores indicating better quality of life. Change is calculated as 1-month follow-up minus baseline, with negative values indicating improvement.
Time frame: From baseline to the 1-month follow-up
Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Score at 3-Month Follow-Up
The PDQ-39 is a 39-item self-report questionnaire assessing health-related quality of life in Parkinson's disease across eight domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Each item is scored 0 (never) to 4 (always). A summary index score is calculated as a percentage (0-100), with lower scores indicating better quality of life. Change is calculated as 3-month follow-up minus baseline, with negative values indicating improvement.
Time frame: From baseline to the 3-month follow-up
Plan to share: Undecided
Start is estimated for Jun 2026; primary completion for Nov 2027, 16 months later.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 16 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
San Francisco Neurology and Sleep Center